Advertisement

Archives of Gynecology and Obstetrics

, Volume 289, Issue 3, pp 601–608 | Cite as

Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women

  • Giampiero CapobiancoEmail author
  • Jean Marie Wenger
  • Giovanni Battista Meloni
  • Margherita Dessole
  • Pier Luigi Cherchi
  • Salvatore Dessole
General Gynecology

Abstract

Purpose

To assess the effects of the combination of pelvic floor rehabilitation, intravaginal estriol and Lactobacillus acidophli administration on stress urinary incontinence (SUI), urogenital atrophy and recurrent urinary tract infections in postmenopausal women.

Methods

136 postmenopausal women with urogenital aging symptoms were enrolled in this prospective randomized study. Patients: randomly divided into two groups and each group consisted of 68 women. Interventions: Subjects in the triple therapy (group I) received 1 intravaginal ovule containing 30 mcg estriol and Lactobacilli acidophili (50 mg lyophilisate containing at least 100 million live bacteria) such as once daily for 2 weeks and then two ovules once weekly for a total of 6 months as maintenance therapy plus pelvic floor rehabilitation. Subjects in the group II received one intravaginal estriol ovule (1 mg) plus pelvic floor rehabilitation in a similar regimen. Mean outcome measures: We evaluated urogenital symptomatology, urine cultures, colposcopic findings, urethral cytologic findings, urethral pressure profiles and urethrocystometry before, as well as after 6 months of treatment.

Results

After therapy, the symptoms and signs of urogenital atrophy significantly improved in both groups. 45/59 (76.27 %) of the group I and 26/63 (41.27 %) of the group II referred a subjective improvement of their incontinence. In the patients treated by triple therapy with lactobacilli, estriol plus pelvic floor rehabilitation, we observed significant improvements of colposcopic findings, and there were statistically significant increases in mean maximum urethral pressure, in mean urethral closure pressure, as well as in the abdominal pressure transmission ratio to the proximal urethra.

Conclusions

Our results showed that triple therapy with L. acidophili, estriol plus pelvic floor rehabilitation was effective and should be considered as first-line treatment for symptoms of urogenital aging in postmenopausal women.

Keywords

Pelvic floor rehabilitation Postmenopausal women Recurrent urinary tract infections Urogenital atrophy Urinary incontinence Lactobacillus acidophili Vaginal estriol 

Notes

Conflict of interest

We declare that we have no conflict of interest.

References

  1. 1.
    Singh S, van Herwijnen I, Phillips C (2013) The management of lower urogenital changes in the menopause. Menopause Int 19:77–81PubMedCrossRefGoogle Scholar
  2. 2.
    Cardozo L, Bachmann G, McClish D, Fonda D, Birgenson L (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. Obstet Gynecol 92:722–727PubMedCrossRefGoogle Scholar
  3. 3.
    Legendre G, Ringa V, Fauconnier A, Fritel X (2013) Menopause, hormone treatment and urinary incontinence at midlife. Maturitas 74:26–30PubMedCrossRefGoogle Scholar
  4. 4.
    Iosif CS, Batra S, Ek A, Astedt B (1981) Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol 141:817–820PubMedGoogle Scholar
  5. 5.
    Smith P (1993) Estrogens and the urogenital tract. Acta Obstet Gynecol Scand 157(suppl):1–25Google Scholar
  6. 6.
    Cadieux PA, Burton J, Devillard E, Reid G (2009) Lactobacillus by-products inhibit the growth and virulence of uropathogenic Escherichia coli. J Physiol Pharmacol 60(Suppl 6):13–18PubMedGoogle Scholar
  7. 7.
    Atassi F, Servin AL (2010) Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain Lactobacillus johnsonii NCC933 and vaginal strain Lactobacillus gasseri KS120.1 against enteric, uropathogenic and vaginosis-associated pathogens. FEMS Microbiol Lett 304:29–38PubMedCrossRefGoogle Scholar
  8. 8.
    Antonio MA, Hillier SL (2003) DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J Clin Microbiol 41:1881–1887PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Raz R (2011) Urinary tract infection in postmenopausal women. Korean J Urol 52:801–808PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaia Y, Fiedler T, Cox M, Stamm WE (2011) Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 52:1212–1217PubMedCrossRefGoogle Scholar
  11. 11.
    Samsioe G, Jansson I, Mellstrom D, Svanborg A (1985) Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. Maturitas 7:335–342PubMedCrossRefGoogle Scholar
  12. 12.
    Nilsson K, Heimer G (1992) Low-dose oestradiol in the treatment of urogenital oestrogen deficiency: a pharmacokinetic and pharmacodynamic study. Maturitas 15:121–127PubMedCrossRefGoogle Scholar
  13. 13.
    Smith P, Heimer G, Lindskog M, Ulmsten U (1993) Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 16:145–154PubMedCrossRefGoogle Scholar
  14. 14.
    Fantl JA, Cardozo L, McClish DK (1994) Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the hormones and urogenital therapy committee. Obstet Gynecol 83:12–18PubMedGoogle Scholar
  15. 15.
    Dessole S, Rubattu G, Ambrosini G, Gallo O, Capobianco G, Cherchi PL, Marci R, Cosmi E (2004) Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 11:49–56PubMedCrossRefGoogle Scholar
  16. 16.
    Esposito G (1991) Estriol: a weak estrogen or a different hormone? Gynecol Endocrinol 5:131–153PubMedCrossRefGoogle Scholar
  17. 17.
    Heimer GM, Englund DE (1992) Effects of vaginally-administered oestriol on post-menopausal urogenital disorders: a cytohormonal study. Maturitas 14:171–179PubMedCrossRefGoogle Scholar
  18. 18.
    Iosif CS (1992) Effects of protracted administration of estriol on the lower genito urinary tract in postmenopausal women. Arch Gynecol Obstet 251:115–120PubMedCrossRefGoogle Scholar
  19. 19.
    Foidart JM, Vervliet J, Buytaert P (1991) Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 13:99–107PubMedCrossRefGoogle Scholar
  20. 20.
    Van der Linden MC, Gerretsen G, Brandhorst MS, Ooms EC, Kremer CM, Doesburg WH (1993) The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito—urinary symptoms. Eur J Obstet Gynecol Reprod Biol 51:29–33PubMedCrossRefGoogle Scholar
  21. 21.
    Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I (1994) A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 171:624–632PubMedCrossRefGoogle Scholar
  22. 22.
    Bottiglione F, Volpe A, Esposito G, De Aloysio D (1995) Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas 22:227–232PubMedCrossRefGoogle Scholar
  23. 23.
    Barentsen R, van de Weijer PH, Schram JH (1997) Continuous low-dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 71:73–80PubMedCrossRefGoogle Scholar
  24. 24.
    Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E (2000) Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 79:293–297PubMedCrossRefGoogle Scholar
  25. 25.
    Kanne B, Jenny J (1991) Local administration of low-dose estriol and vital Lactobacillus acidophilus in postmenopause. Gynakol Rundsch 31:7–13PubMedCrossRefGoogle Scholar
  26. 26.
    Raz R, Stamm WE (1993) A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329:753–756PubMedCrossRefGoogle Scholar
  27. 27.
    Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi Pl, Dessole S (2012) Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet 285:397–403PubMedCrossRefGoogle Scholar
  28. 28.
    Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC (2004) Duloxetine urinary incontinence study group. Duloxetine versus placebo for the treatment of Noth American women with stress urinary incontinence. J Urol 170:1259–1263CrossRefGoogle Scholar
  29. 29.
    Berghmans LCM, Hendrikis HJM, Bo K, Hay-Smith EJ, de Bies RA, van Waalwijk, van Doorn ESC (1998) Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials. Br J Urol 82:181–189PubMedCrossRefGoogle Scholar
  30. 30.
    Castro RA, Arruda RM, Zanetti MRD, Santos PD, Sartori MGF, Girao MJBC (2008) Single-blind, randomized, controlled trial of pelvic floor muscle training, electrical stimulation, vaginal cones, and no active treatment in the management of stress urinary incontinence. Clinics 63:465–472PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Leriche B, Conquy S (2010) Guidelines for rehabilitation management of non-neurological urinary incontinence in women. Prog Urol 20:S104–S108PubMedCrossRefGoogle Scholar
  32. 32.
    Archer DF (2010) Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 17:194–203PubMedCrossRefGoogle Scholar
  33. 33.
    Ishiko O, Hirai K, Sumi T, Tatsuta I, Ogita S (2001) Hormone replacement therapy plus pelvic floor muscle exercise for postmenopausal stress incontinence. A randomized, controlled trial. J Reprod Med 46:213–220PubMedGoogle Scholar
  34. 34.
    Schar G, Kochli OR, Fritz M, Heller U (1995) Effect of vaginal estrogen therapy on urinary incontinence in postmenopause. Zentralbl Gynakol 117:77–80PubMedGoogle Scholar
  35. 35.
    Lose G, Englev E (2000) Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 107:1029–1034PubMedCrossRefGoogle Scholar
  36. 36.
    Bhatia NN, Bergman A, Karram MM (1989) Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol 160:176–181PubMedCrossRefGoogle Scholar
  37. 37.
    Hilton P, Stanton SL (1983) The use of intravaginal estrogen cream in genuine stress incontinence. Br J Obstet Gynaecol 90:940–944PubMedCrossRefGoogle Scholar
  38. 38.
    Sturdee DW, Panay N (2010) International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13:509–522PubMedCrossRefGoogle Scholar
  39. 39.
    Jaisamrarn U, Triratanachat S, Chaikittisilpa S, Grob P, Prasauskas V, Taechakraichana N (2013) Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. Climacteric 16:347–355PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Giampiero Capobianco
    • 1
    Email author
  • Jean Marie Wenger
    • 2
  • Giovanni Battista Meloni
    • 3
  • Margherita Dessole
    • 1
  • Pier Luigi Cherchi
    • 1
  • Salvatore Dessole
    • 1
  1. 1.Department of Surgical, Microsurgical and Medical Sciences Gynecologic and Obstetric ClinicUniversity of SassariSassariItaly
  2. 2.Gynecologic and Obstetric ClinicUniversity of GinevraGinevraSwitzerland
  3. 3.Department of Surgical, Microsurgical and Medical Sciences, Institute of RadiologyUniversity of SassariSassariItaly

Personalised recommendations